Diagnosis and Treatment of Infections due to Mycobacterium avium Complex

ABSTRACT

Mycobacterium avium complex (MAC) consists of nontuberculous mycobacteria that cause disease in immunocompromised and immunocompetent hosts. The organisms are ubiquitous in the environment, and acquisition occurs through ingestion or inhalation of aerosols from soil, water, or biofilms. Disease may manifest as disseminated infection, soft tissue infection, chronic pneumonia, or hypersensitivity pneumonitis. Nontuberculous mycobacteria are increasingly associated with pulmonary disease, with MAC being the most common nontuberculous mycobacteria to cause pulmonary disease in the United States. Pulmonary symptoms, nodular or cavitary opacities on a chest radiograph or high-resolution computed tomographic scan with multifocal bronchiectasis and multiple small nodules, plus positive culture results from two sputum specimens or one bronchoscopic specimen are consistent with MAC pulmonary disease. Treatment consists of a macrolide, rifamycin, and ethambutol given three times weekly for noncavitary disease and daily with or without an aminoglycoside for cavitary disease.

KEYWORDS

Mycobacterium avium complex - nontuberculous mycobacteria - diagnosis - treatment

REFERENCES

• 1 Turenne C Y, Wallace Jr R, Behr M A. Mycobacterium avium in the postgenomic era.  Clin Microbiol Rev. 2007;  20 205-229
• 2 Falkinham III J O. Nontuberculous mycobacteria in the environment.  Clin Chest Med. 2002;  23 529-551
• 3 Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria.  Clin Chest Med. 2002;  23 553-567
• 4 Khan K, Wang J, Marras T K. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades.  Am J Respir Crit Care Med. 2007;  176 306-313
• 5 Marras T K, Chedore P, Ying A M, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003.  Thorax. 2007;  62 661-666
• 6 Griffith D E, Aksamit T, Brown-Elliott B A et al.. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
• 7 Pasteur M C, Helliwell S M, Houghton S J et al.. An investigation into causative factors in patients with bronchiectasis.  Am J Respir Crit Care Med. 2000;  162(4 Pt 1) 1277-1284
• 8 Field S K, Fisher D, Cowie R L. Mycobacterium avium complex pulmonary disease in patients without HIV infection.  Chest. 2004;  126 566-581
• 9 Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin J P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.  Chest. 1995;  107 1035-1040
• 10 Wallace Jr R J, Brown B A, Griffith D E et al.. Initial clarithromycin monotherapy for Mycobacterium avium–intracellulare complex lung disease.  Am J Respir Crit Care Med. 1994;  149 1335-1341
• 11 Griffith D E, Brown B A, Girard W M, Murphy D T, Wallace Jr R J. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 983-989
• 12 Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.  J Infect Chemother. 2006;  12 195-202
• 13 Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan—including a follow-up study.  Respiration. 2007;  74 394-400
• 14 Kuwabara K, Tsuchiya T. Clinical features and treatment history of clarithromycin resistance in M. avium–intracellulare complex pulmonary disease patients [in Japanese].  Nihon Kokyuki Gakkai Zasshi. 2007;  45(8) 587-592
• 15 Griffith D E, Brown-Elliott B A, Langsjoen B et al.. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.  Am J Respir Crit Care Med. 2006;  174 928-934
• 16 Kohno Y, Ohno H, Miyazaki Y et al.. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.  Antimicrob Agents Chemother. 2007;  51 4071-4076
• 16a Kasperbauer S, Wilson S E, Graham J J, Heifets L, Daley C. Fluoroquinolone susceptibility in non-tuberculous mycobacteria. Presented at: The American Thoracic Society International Conference May 23, 2007 San Francisco, CA; Abstract p. 971
• 17 Griffith D E, Brown B A, Girard W M, Griffith B E, Couch L A, Wallace Jr R J. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.  Clin Infect Dis. 2001;  32 1547-1553
• 18 Griffith D E, Brown B A, Cegielski P, Murphy D T, Wallace Jr R J. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.  Clin Infect Dis. 2000;  30 288-292
• 19 Lam P K, Griffith D E, Aksamit T R et al.. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease.  Am J Respir Crit Care Med. 2006;  173 1283-1289
• 20 Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease.  Respir Med. 2007;  101 130-138
• 21 Jenkins P A, Campbell I A, Banks J, Gelder C M, Prescott R J, Smith A P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.  Thorax. 2008;  63 627-634
• 22 Kuroishi S, Nakamura Y, Hayakawa H et al.. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings.  Eur Respir J. 2008;  32 147-152
• 23 Horsburgh Jr C R. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.  N Engl J Med. 1991;  324 1332-1338
• 24 Chin D P, Hopewell P C, Yajko D M et al.. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection.  J Infect Dis. 1994;  169 289-295
• 25 von Reyn C F, Maslow J N, Barber T W, Falkinham III J O, Arbeit R D. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS.  Lancet. 1994;  343 1137-1141
• 26 Benson C A. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome.  Clin Infect Dis. 1994;  18(Suppl 3) S218-S222
• 27 Benson C A, Kaplan J E, Masur H, Pau A, Holmes K K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.  MMWR Recomm Rep. 2004;  53(RR-15) 1-112
• 28 Benson C A, Williams P L, Currier J S et al.. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.  Clin Infect Dis. 2003;  37 1234-1243
• 29 Gordin F M, Sullam P M, Shafran S D et al.. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex.  Clin Infect Dis. 1999;  28 1080-1085
• 30 Corti M, Villafane M F, Ambroggi M, Sawicki M, Gancedo E. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy.  Rev Inst Med Trop Sao Paulo. 2007;  49 267-270
• 31 Phillips P, Bonner S, Gataric N et al.. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.  Clin Infect Dis. 2005;  41 1483-1497
• 32 Shelburne III S A, Hamill R J. The immune reconstitution inflammatory syndrome.  AIDS Rev. 2003;  5 67-79
• 33 Salvana E M, Cooper G S, Salata R A. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients.  J Infect. 2007;  55 484-487
• 34 Olsen R J, Cernoch P L, Land G A. Mycobacterial synovitis caused by slow-growing nonchromogenic species: eighteen cases and a review of the literature.  Arch Pathol Lab Med. 2006;  130 783-791
• 35 Hellinger W C, Smilack J D, Greider Jr J L et al.. Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist.  Clin Infect Dis. 1995;  21 65-69
• 36 Maltezou H C, Spyridis P, Kafetzis D A. Nontuberculous mycobacterial lymphadenitis in children.  Pediatr Infect Dis J. 1999;  18 968-970
• 37 Liao C H, Lai C C, Ding L W et al.. Skin and soft tissue infection caused by non-tuberculous mycobacteria.  Int J Tuberc Lung Dis. 2007;  11 96-102
• 38 Hanak V, Golbin J M, Ryu J H. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis.  Mayo Clin Proc. 2007;  82 812-816
• 39 Marras T K, Wallace Jr R J, Koth L L, Stulbarg M S, Cowl C T, Daley C L. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water.  Chest. 2005;  127 664-671
• 40 Hartman T E, Jensen E, Tazelaar H D, Hanak V, Ryu J H. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium–intracellulare inhalation: “hot tub lung”.  AJR. 2007;  188 1050-1053
• 41 Hanak V, Kalra S, Aksamit T R, Hartman T E, Tazelaar H D, Ryu J H. Hot tub lung: presenting features and clinical course of 21 patients.  Respir Med. 2006;  100 610-615
• 42 Centers for Diseases Control and Prevention . Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria—Ohio, 2001.  JAMA. 2002;  287 3073-3074
• 43 Centers for Disease Control and Prevention (CDC) . Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria—Ohio, 2001.  MMWR Morb Mortal Wkly Rep. 2002;  51 349-352